Tirzepatide vs Semaglutide Side Effects: An Honest Side-by-Side

If you are trying to choose between these two shots, or just wondering whether the other one would have treated your stomach more kindly, here is the honest answer: they cause the same kinds of side effects. Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist. Tirzepatide (Mounjaro, Zepbound) acts on two receptors, GIP and GLP-1. Despite that difference, both slow how fast your stomach empties and act on the brain's appetite and nausea pathways, so nausea, vomiting, diarrhea, and constipation lead the list for both. The symptoms are usually mild to moderate, worst when you start or step up a dose, and they tend to settle as your body adjusts. Which one your body tolerates better is something only a prescribing clinician can judge with you. This is general information, not medical advice.

They are more alike than different

It is natural to assume that because tirzepatide works on an extra receptor, it must feel completely different to take. In the ways that matter to your stomach, it mostly does not.

Both medicines act on the GLP-1 receptor, which slows how quickly food leaves your stomach and engages the appetite and nausea centers in the brain. The practical result is the same for both: the side effects people report most are digestive ones. Nausea, vomiting, diarrhea, and constipation are the headliners on both shots.

Three things hold true across the trial evidence for each drug, and they are worth holding onto if you are anxious tonight:

• The dose matters. Higher doses tend to bring more stomach trouble.
• The start and the step-ups are the hard part. Symptoms cluster when you begin the medicine and when the dose goes up, then ease.
• For most people it is a rough patch, not a wall. These effects are usually mild to moderate and calm down as the body adapts, rather than a reason to stop.

Tirzepatide's extra GIP activity does not change this overall shape. Its side-effect profile stays digestion-dominant and in keeping with the class. For more on the symptoms themselves, see our overview of GLP-1 side effects and the detail page on nausea.

Tirzepatide vs semaglutide side effects, side by side

Here is the part most people come looking for: the numbers, laid out next to each other. Please read this table as background for a conversation with your prescriber, not as a scoreboard.

One thing matters before you look. The semaglutide nausea figure (about 44 percent) and the tirzepatide nausea figures (about 25 to 33 percent) come from separate trials with different people in them, not from a head-to-head where both drugs were tested side by side in the same study. That difference is bigger than it sounds, and we explain why a little further down. Treat these as two studies placed near each other, not a fair race.

For the underlying per-symptom rates from each separate trial, here is the detail behind the nausea row above:

Sources: pooled STEP semaglutide rates and SURMOUNT-1 tirzepatide per-dose rates.

What the one fair head-to-head actually showed

There is exactly one trial that put these two medicines against each other in the same obesity study, called SURMOUNT-5. It ran 72 weeks at each person's maximum tolerated dose. Because it is the only apples-to-apples comparison, it is the most trustworthy place to look, and its published report gives overall figures by group rather than a clean per-symptom breakdown:

A few honest notes on this table. The weight-loss row (about 20.2 percent for tirzepatide versus about 13.7 percent for semaglutide) is a SURMOUNT-5 finding about how much weight each group lost on average, and we include it only because it comes from this fair head-to-head. It is not a promise about what will happen for you, and it is not a side-effect measure. On the side effects themselves, the two were close: any-adverse-event rates were about 77 versus 79 percent, and slightly fewer people stopped tirzepatide because of side effects. But serious adverse events ran a touch the other way, numerically higher with tirzepatide. So there is no clean "this one is safer" conclusion to draw.

In type 2 diabetes, the SURPASS-2 head-to-head compared tirzepatide against semaglutide 1 mg, the diabetes dose, not the 2.4 mg obesity dose, and found broadly overlapping stomach-related rates: nausea 18 percent (semaglutide) versus 17 to 22 percent (tirzepatide across doses), diarrhea 12 percent versus 13 to 16 percent, and discontinuation 4.1 percent versus 6.0 to 8.5 percent.

Why you cannot just subtract one column from the other

It is tempting to look at "44 percent nausea" next to "25 to 33 percent nausea" and declare a winner. The evidence does not support that, and we would rather be straight with you than let a tidy number mislead you:

• The separate-trial rates are not a fair race. The STEP program (semaglutide) and SURMOUNT-1 (tirzepatide) enrolled different people, with different starting weights, other medicines, and step-up schedules. A gap between them can reflect the studies as much as the drugs.
• The diabetes trial used a smaller dose. SURPASS-2 compared tirzepatide against semaglutide 1 mg, the diabetes dose, not the 2.4 mg used for weight management, so its rates should not be read as an obesity comparison.
• Even the fair trial has limits. SURMOUNT-5 is the only head-to-head in obesity, and even there the per-symptom breakdown by group is behind a paywall and was not verified, which is why we report only its overall figures.
• Trial design shapes the stopping numbers. SURMOUNT-5 was open-label and titrated to each person's maximum tolerated dose, both of which influence how many people stop and why.

For how these effects typically ease over the first weeks and months, see how long GLP-1 side effects last.

So which one is gentler?

Here is what this comparison can honestly tell you, and what it cannot.

What it can tell you: both medicines cause the same digestive class of side effects, mostly mild to moderate, worst during the early dose step-ups and easing over time. In the one fair head-to-head in obesity, the two were similar overall, with slightly fewer people stopping tirzepatide because of side effects.

What it cannot tell you is the thing you most want to know: which one your body, specifically, will tolerate better. Trial averages do not predict one person's experience, and these figures are not a safety ranking, since the serious-adverse-event signal actually ran the other way. Choosing between them is a decision to make with a prescribing clinician who knows your history, your goals, and how your body responds. This page does not recommend either medicine, and it sells nothing.

Questions people ask at 11pm

Which has fewer side effects, semaglutide or tirzepatide? Neither one cleanly wins. In the only fair obesity head-to-head, SURMOUNT-5, overall adverse-event rates were similar, about 77 versus 79 percent, and slightly fewer people stopped tirzepatide because of side effects. But serious adverse events ran a touch higher with tirzepatide, so it is not a safety ranking. They share the same stomach-dominant profile, and only a clinician can judge which suits you.

Can I compare those trial percentages directly? Not reliably. The semaglutide nausea figure (about 44 percent) and the tirzepatide figures (about 25 to 33 percent) come from separate trials with different people and different doses, so subtracting one from the other to claim a tolerability gap is misleading. Only SURMOUNT-5 compared them head-to-head in obesity, and it reports overall, not per-symptom, numbers.

Should I switch to the other one because my stomach is struggling? Please do not make that call alone or change anything on your own. Because both medicines cause the same kind of side effects, switching is not a guaranteed fix, and the smartest first move is often a slower, prescriber-guided step-up on the medicine you are already taking. Bring your symptoms to your prescriber and decide together.

How we reviewed this: written from peer-reviewed trial sources, including the pooled STEP semaglutide rates, the SURMOUNT-1 tirzepatide trial, the SURPASS-2 head-to-head in diabetes, and the SURMOUNT-5 head-to-head in obesity. See our editorial and review policy and sourcing standards. The semaglutide and tirzepatide rates quoted side by side come from separate trials with different populations, baseline weights, background medicines, and doses, so we present them next to each other without subtracting them, and where head-to-head per-symptom data is paywalled we say so rather than invent it.